ArticlePituitary2026
Natural history of non-functioning pituitary neuroendocrine tumours: impact of baseline characteristics and gender-specific clinical presentations.
Article in Pituitary, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-functioning pituitary neuroendocrine tumours (NF-PitNETs) are the most common pituitary macroadenomas, with highly variable clinical behaviour. Although tumor growth and functional impairment are key considerations, the impact of patient sex on presentation and outcomes remains incompletely characterized.
objectiveTo investigate clinical, radiological and histopathological predictors of long-term outcomes in NF-PitNETs managed conservatively or surgically and to evaluate gender impact on initial presentation and tumour natural history.
methodsWe retrospectively analyzed 170 patients with NF-PitNETs, including those under active surveillance and those treated surgically, with or without adjuvant therapies. Long-term clinical, endocrine and radiological follow-up was performed.
resultsCompared with female patients, males exhibited larger tumour dimensions and a higher prevalence of both visual field defects and endocrine dysfunction. Women, particularly in the surveillance cohort, had smaller tumours, often detected earlier, likely due to reproductive-age clinical monitoring. Despite these baseline differences, progression rates were similar between genders. In patients under surveillance, five-year tumour growth risk was higher for macroadenomas than microadenomas (45.7% vs. 22.5%, p = 0.030), and baseline tumour volume and visual impairment predicted progression. In the surgical cohort, residual tumour increased progression risk, while a > 40% volume reduction was associated with visual improvement. The Trouillas clinicopathological classification was not predictive of outcomes. Adjuvant therapies, including stereotactic radiosurgery and temozolomide, stabilized disease in most treated cases.
conclusionsGender significantly influences NF-PitNETs presentation, with males harbouring larger, more symptomatic tumours whereas females tended to have an earlier detection. However, long-term progression seems to be independent of gender. These findings pinpoint the importance of individualized approach combining anatomical, volumetric, and functional assessments to optimize outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.